Dr Andrew Dean, Board Member, completed his medical training in the UK, became a fellow of the Royal Australian College of Physicians in 1993. He established the palliative care services at Sir Charles Gairdner Hospital and St John of God Subiaco in Perth, later becoming professor of palliative medicine at Edith Cowan University Western Australia.
Sari Pesonen, Chief Scientific Officer (PhD, co-founder), has held scientific leadership roles in immuno-oncology biotech companies and has vast experience in clinical drug development. She joined Oncos Therapeutics as a Research Director and later took on the role of Head of Clinical Science, leading clinical sample analysis, which for the first time demonstrated the mode of action of oncolytic adenovirus-based cancer immunotherapy. Later, Sari worked as VP Preclinical Research and Clinical Science at Targovax.
David is an experienced executive in the ASX listed environment.
Associate Professor Paul Porter (MBBS, FRACP), Director, is the founder of Freeman Road Pty Ltd, an Australian company that specialises in early stage biomedical investments with an emphasis on global research and development collaborations. Freeman Road has investments in companies across Australia, South East Asia, Europe and the USA.